BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36960584)

  • 21. F-18 FDG PET/CT imaging in the diagnostic work-up of thyroid cancer patients with high serum thyroglobulin, negative I-131 whole body scan and suppressed thyrotropin: 8-year experience.
    Elboga U; Karaoglan H; Sahin E; Kalender E; Demir HD; Basıbuyuk M; Zeki Celen Y; Yilmaz M; Ozkaya M
    Eur Rev Med Pharmacol Sci; 2015; 19(3):396-401. PubMed ID: 25720709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Follicular Thyroid Carcinoma with Unusual Radioiodine-Refractory Breast Metastasis Mimicking Primary Breast Malignancy.
    Jain TK; Krishnaraju VS; Mittal BR; Sood A; Kumar R; Garg R; Kumar S
    J Nucl Med Technol; 2021 Sep; 49(3):288-289. PubMed ID: 33722923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG PET/CT concurrent with first radioiodine post-therapeutic scan in high risk differentiated thyroid cancer: a useful tool or just an expensive diversion?
    Rizzo A; Perotti G; Zagaria L; Lanni V; Racca M; Palestini N; Salvatori M
    Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):158-166. PubMed ID: 35238517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
    Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
    Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.
    Leboulleux S; El Bez I; Borget I; Elleuch M; Déandreis D; Al Ghuzlan A; Chougnet C; Bidault F; Mirghani H; Lumbroso J; Hartl D; Baudin E; Schlumberger M
    Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast metastasis in follicular thyroid cancer patient.
    Ertürk SA; Hasbek Z; Duman G; Sariakçali B
    J Cancer Res Ther; 2022 Dec; 18(Supplement):S486-S488. PubMed ID: 36511011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas.
    Giovanella L; Ceriani L; De Palma D; Suriano S; Castellani M; Verburg FA
    Head Neck; 2012 May; 34(5):626-31. PubMed ID: 21850699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bronchoalveolar carcinoma of lung masquerading as iodine avid metastasis in a patient with minimally invasive follicular carcinoma of thyroid.
    Malhotra G; Nair N; Menon H; Gujral S; Abhyankar A; Baghel NS; Awasare S; Nabar SJ; Abhyankar S; Kand PG
    Clin Nucl Med; 2008 Jan; 33(1):26-9. PubMed ID: 18097252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-therapy hyperfunctioning follicular thyroid carcinoma evaluation with I-131 whole-body scan and with F-18 FDG PET/CT.
    Orsolon P; Giachetti M; Lupi A; Salgarello M; Malfatti V; Zanco P
    Clin Nucl Med; 2008 Dec; 33(12):882-6. PubMed ID: 19033798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].
    Ruiz Franco-Baux JV; Borrego Dorado I; Gómez Camarero P; Rodríguez Rodríguez JR; Vázquez Albertino RJ; Navarro González E; Astorga Jiménez R
    Rev Esp Med Nucl; 2005; 24(1):5-13. PubMed ID: 15701340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?
    Giammarile F; Hafdi Z; Bournaud C; Janier M; Houzard C; Desuzinges C; Itti R; Sassolas G; Borson-Chazot F
    Eur J Endocrinol; 2003 Oct; 149(4):293-300. PubMed ID: 14514343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma.
    Lee J; Nah KY; Kim RM; Oh YJ; An YS; Yoon JK; An GI; Choi TH; Cheon GJ; Soh EY; Chung WY
    J Korean Med Sci; 2012 Sep; 27(9):1019-26. PubMed ID: 22969247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival.
    Valerio L; Guidoccio F; Giani C; Tardelli E; Puccini G; Puleo L; Minaldi E; Boni G; Elisei R; Volterrani D
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2355-2366. PubMed ID: 33901285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positron Emission Tomography/Computed Tomography in Thyroid Cancer.
    Bal C; Chakraborty D; Khan D
    PET Clin; 2022 Apr; 17(2):265-283. PubMed ID: 35256297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
    Hung MC; Wu HS; Kao CH; Chen WK; Changlai SP
    Endocr Res; 2003 May; 29(2):169-75. PubMed ID: 12856803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.